Literature DB >> 25564000

Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer.

Ismail Alay1, Taner Turan, Isin Ureyen, Alper Karalok, Tolga Tasci, Ahmet Ozfuttu, M Faruk Kose, Gokhan Tulunay.   

Abstract

We aimed to evaluate para-aortic metastases relative to the level of inferior mesenteric artery (IMA) and to discuss the clinico-pathological features of these patients. A total of 204 patients who underwent systematic pelvic and para-aortic lymphadenectomy up to the level of renal veins for endometrial cancer between January 2007 and August 2013 were included in this study. Of these 204 patients, 44 (21.6 %) had lymph node involvement. From a total of 27 patients with paraaortic lymph node (PALN) metastasis, 11 had only supramesenteric and 4 had only inframesenteric nodal involvement, while 12 had both supramesenteric and inframesenteric metastases. Supramesenteric lymph node metastases were detected in 85.2 % of patients who have para-aortic metastases and in 11.3 % of all patients. Additionally, 5 patients had only supramesenteric lymphatic metastasis. The surgico-pathological characteristics of patients with isolated supramesenteric and inframesenteric metastasis were similar. However, the patients with lymphatic spread in both regions were found to have pelvic lymphatic metastasis and cervical invasion more commonly compared to patients with only supramesenteric or only inframesenteric metastasis. The site of metastatic lymph nodes wasn't associated with the likelihood and site of recurrence. Lymphadenectomy should be performed up to the level of renal vein in case of the presence of indication for lymphadenectomy in patients with endometrial cancer. Additionally, it is not possible to predict the patients with supramesenteric lymph node involvement by tumor grade, histological type and myometrial invasion.

Entities:  

Mesh:

Year:  2015        PMID: 25564000     DOI: 10.1007/s12253-014-9893-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  22 in total

1.  Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer.

Authors:  H Nomura; D Aoki; N Suzuki; N Susumu; A Suzuki; Y Tamada; F Kataoka; A Higashiguchi; S Ezawa; S Nozawa
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

2.  Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma.

Authors:  Suk-Joon Chang; Woo Young Kim; Jong-Hyuck Yoon; Seung-Chul Yoo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  Acta Obstet Gynecol Scand       Date:  2008       Impact factor: 3.636

3.  Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.

Authors:  Sanjeev Kumar; Karl C Podratz; Jamie N Bakkum-Gamez; Sean C Dowdy; Amy L Weaver; Michaela E McGree; William A Cliby; Gary L Keeney; Gillian Thomas; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2013-10-09       Impact factor: 5.482

4.  Distribution of lymph node metastasis sites in endometrial cancer undergoing systematic pelvic and para-aortic lymphadenectomy: a proposal of optimal lymphadenectomy for future clinical trials.

Authors:  Tetsuji Odagiri; Hidemichi Watari; Tatsuya Kato; Takashi Mitamura; Masayoshi Hosaka; Satoko Sudo; Mahito Takeda; Noriko Kobayashi; Peixin Dong; Yukiharu Todo; Masataka Kudo; Noriaki Sakuragi
Journal:  Ann Surg Oncol       Date:  2014-04-05       Impact factor: 5.344

5.  Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers.

Authors:  Y Yokoyama; H Maruyama; S Sato; Y Saito
Journal:  Gynecol Oncol       Date:  1997-03       Impact factor: 5.482

6.  Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status.

Authors:  Christina Fotopoulou; Konstantinos Savvatis; Robert Kraetschell; Joerg C Schefold; Werner Lichtenegger; Jalid Sehouli
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-01-22       Impact factor: 2.435

7.  FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.

Authors:  Anna V Hoekstra; Robert J Kim; William Small; Alfred W Rademaker; Irene B Helenowski; Diljeet K Singh; Julian C Schink; John R Lurain
Journal:  Gynecol Oncol       Date:  2009-05-09       Impact factor: 5.482

8.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

Authors:  Andrea Mariani; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Monica B Jones; Timothy O Wilson; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2008-03-04       Impact factor: 5.482

9.  Endometrial carcinoma: paraaortic dissemination.

Authors:  Andrea Mariani; Gary L Keeney; Giacomo Aletti; Maurice J Webb; Michael G Haddock; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

10.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

Authors:  H Kitchener; A M C Swart; Q Qian; C Amos; M K B Parmar
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

View more
  1 in total

1.  Implications of para-aortic lymph node metastasis in patients with endometrial cancer without pelvic lymph node metastasis.

Authors:  Yukiharu Todo; Sho Takeshita; Kazuhira Okamoto; Katsushige Yamashiro; Hidenori Kato
Journal:  J Gynecol Oncol       Date:  2017-05-22       Impact factor: 4.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.